Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant929 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07151326 | Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy(CAPIO) | not yet recruiting | Phase 2 | 60 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07150377 | A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 41 | The Second Affiliated Hospital of Shandong First Medical University |
| 0 |
| Sep 2, 2025 |
| clinicaltrials |
| NCT06541990 | Psychoeducational Intervention for Patients With Hepatocellular Carcinoma(HARMONY) | recruiting | N/A | 50 | Massachusetts General HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07142876 | Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA). | not yet recruiting | N/A | 50 | Sohag UniversityOTHER | 0 | Aug 27, 2025 | clinicaltrials |
| NCT06374485 | Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment | recruiting | Phase 1 | 18 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07141056 | The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study(SOLACE) | recruiting | — | 700 | Guilin Medical University, ChinaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07142213 | Effect and Mechanism of ALPPS Operation on Liver Regeneration | recruiting | — | 50 | Haitao Zhao, MDOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | recruiting | Phase 1 | 21 | GONGCHU Biotechnology Co., LtdOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06777485 | China Liver Cancer Clinical Registry Cohort Database (HEAL) | recruiting | — | 10,000 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07131501 | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06084299 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer | recruiting | Phase 1 | 16 | Zhiyong HuangOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130474 | Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma | not yet recruiting | — | 50 | Sohag UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07100392 | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-02) | recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07100405 | TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment(TASK-01-RW) | recruiting | — | 50 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07105748 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)(TASK-05) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07128251 | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | not yet recruiting | Phase 2 | 47 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07128290 | PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma(PEHRICCA) | not yet recruiting | Phase 2 | 49 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05613621 | Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies(T4222) | active not recruiting | — | 579 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06280313 | Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension | recruiting | — | 60 | Zhiyong HuangOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1) | active not recruiting | Phase 2 | 130 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT06323382 | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | recruiting | — | 240 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06740370 | TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma | recruiting | N/A | 32 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07123545 | Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05433467 | CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection(CTMH) | recruiting | N/A | 5 | Northern Jiangsu People's HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07120750 | Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis(PRTRAS 001) | not yet recruiting | — | 332 | Shenzhen Third People's HospitalOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07070700 | Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-02) | recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07117279 | A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma | not yet recruiting | — | 120 | Tongji HospitalOTHER | 0 | Aug 12, 2025 | clinicaltrials |
| NCT07118735 | AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy(NCKUH) | not yet recruiting | N/A | 94 | National Cheng-Kung University HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07115550 | A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | not yet recruiting | N/A | 24 | Huai'an First People's HospitalOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT05265208 | Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer(SIROCHO) | recruiting | Phase 2 | 62 | Center Eugene MarquisOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05690048 | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)(FLORA) | recruiting | Phase 2 | 48 | Michael DillOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06541652 | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers(FFCD-2205) | recruiting | — | 150 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06551272 | Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma(MOTHER) | recruiting | Phase 2 | 34 | Center Eugene MarquisOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05953961 | 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia(REALM) | recruiting | N/A | 50 | Ochsner Health SystemOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07100236 | 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness | not yet recruiting | — | 350 | Junjie XuOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101237 | An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer. | recruiting | — | 308 | Peking Union Medical College HospitalOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | recruiting | Phase 3 | 132 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03651154 | Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections(PRICE2) | active not recruiting | N/A | 440 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04186234 | SBRT for Liver Cancer Before Liver Transplantation | active not recruiting | N/A | 71 | The University of Hong KongOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06695026 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 45 | Rznomics, Inc.OTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07091942 | Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma | recruiting | — | 1,600 | National Taiwan University HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07088133 | Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus | not yet recruiting | N/A | 12 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 28, 2025 | clinicaltrials |
| NCT06819566 | Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC(ESCOAT) | recruiting | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06031285 | Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06681818 | Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy | recruiting | N/A | 125 | Englewood Hospital and Medical CenterOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07059936 | Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver) | recruiting | — | 350 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077356 | Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077369 | WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 3, 2025source: clinicaltrials